Progenics Pharmaceuticals (PGNX) 10-Q2007 Q3 Quarterly report

Filed: 8 Nov 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abandon, accentuated, accident, accidental, administer, administered, Adolor, advantage, advertising, afforded, ahead, alter, altogether, alvimopan, anniversary, antagonist, asserted, assist, attempting, Australian, avoid, aware, belonging, bowel, branch, breach, breadth, brought, budgetary, build, bulk, burn, Canada, Canadian, capability, cease, censure, chemotherapy, civil, claim, claiming, clear, compete, complementary, compromise, conclusion, conclusive, confidence, confidential, confidentiality, conjugate, contamination, convenient, costly, coverage, credibility, criminal, cured, decide, deductible, demand, demonstrate, directly, director, disagreement, discourage, disposal, disposing, dispute, disruption, distribute, distribution, diversified, division, Draft, dysfunction, enable, enacted, encounter, endeavor, enjoin, Entereg, EnteregTM, environmental, eventual, exceed, expansion, experienced, experiencing, export, fail, fashion, fluctuated, foreign, function, Glaxo, GlaxoSmithKline, Good, handle, handling, HCV, hernia, hostile, inconclusive, increasingly, induced, infrastructure, infringe, infringement, injury, instance, institution, institutional, insufficient, introducing, invention, labeling, laparoscopy, laparotomy, large, Law, lengthy, letter, liable, licensor, line, liver, local, managerial, marketplace, meantime, negative, negotiate, negotiating, notice, novelty, obsolete, offer, offering, optimization, organization, orthopedic, outset, overcome, overlapping, pace, past, patient, PDUFA, pending, penetrate, peripheral, play, plc, POI, population, postoperative, precedent, preclude, preferred, premium, prescription, prevail, procedure, professional, profile, prohibitively, promotion, protect, protection, proven, quality, radioactive, rapid, raw, recombinant, reconfigure, reduction, reformulation, rehabilitating, remedy, removal, reoffer, repair, retrospective, role, route, satisfactory, scale, scheduling, scope, seizure, setback, shown, similarly, slower, spill, statutory, storage, strategic, strength, succeed, suitable, supply, surgical, suspend, takeover, tentative, tentatively, train, trend, unable, unacceptable, unamortized, unanticipated, unauthorized, underwriting, undesirable, undue, unpatented, unwilling, uphold, User, validity, ventral, verify, viewed, violate, waste, withdrawal, written

Removed: built, consideration, expanding, incentive, investing, melanoma, unchanged

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PGNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT

TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned hereby certifies, in his capacity as an officer of Progenics Pharmaceuticals, Inc. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

(1)	The Quarterly Report of the Company on Form 10-Q for the period ended September 30, 2007 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.

Date: November 8, 2007	/s/ Paul J. Maddon, M.D., Ph.D.
	Paul J. Maddon, M.D., Ph.D. Chief Executive Officer


	/s/ Robert A. McKinney
	Robert A. McKinney Chief Financial Officer (Principal Finance and Accounting Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Progenics Pharmaceuticals, Inc. and will be retained by Progenics Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.